Reata Pharma (RETA) Tops Q3 EPS by 89c; Reports Cash and Cash Equivalents of $713.2M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RETA Hot Sheet
Join SI Premium – FREE
Reata Pharma (NASDAQ: RETA) reported Q3 EPS of ($1.27), $0.89 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $2.07 million.
For earnings history and earnings-related data on Reata Pharma (RETA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Envista Holdings Corp. (NVST) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY26 Guidance
- Inter Parfums (IPAR) Tops Q3 EPS by 33c ; Offers Guidance
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
